BioTherapeutics licenses New CRISPR-Cas Gene Editing Technology
Excision BioTherapeutics, a company focused on the development and commercialization of advanced gene editing therapeutics for the treatment of life-threatening disease caused by viruses, has now secured exclusive licenses from UC Berkeley for their newly discovered CRISPR gene editors.
As part of the deal, Excision has secured licenses to explore the gene editors as they relate to infectious diseases, including the Herpes simplex virus.
In February 2017, Drs. Jennifer Doudna and Jillian Banfield published a paper in Nature, indicating the discovery of new CRISPR-Cas systems from uncultivated microbes and opening the door for the development of new versions of the genome editing technology.
Excision BioTherapeutics is the first company to secure licenses to further explore these gene editors as they relate to infectious diseases, including HSV, HBV, HTLV-1, and many other viruses, opening up more ways than ever before to explore possible treatments and/or cures.
In addition to improving its research capabilities and expanding its pipeline, the licenses give Excision BioTherapeutics the right to sub-license these editors to others, such as pharmaceutical companies, providing them with new research alternatives to develop medicines or treatments.
“The discoveries made by the Doudna and Banfield laboratories open up so many possibilities. As a result of their incredible work to develop these alternatives in the gene editing space, we can now take our expertise and intellectual property and make significant progress in medical treatment options for some of the world’s worst infectious diseases,
” said Thomas Malcolm, Ph.D., founder, president and CEO of Excision BioTherapeutics.Dr. Malcolm said Excision is looking to use the nucleases it is licensing from UC Berkeley in addition to Cas9, in order to expand its pipeline of treatments. The company has added to its pipeline EBT105, a herpes simplex virus type 2 (HSV-2) candidate that applies gene editing through a triplex guide RNA (gRNA) excision knockout, and EBT106, a hepatitis B virus candidate that uses a duplex gRNA excision knockout.
Excision’s pipeline is anchored by EBT101, a human immunodeficiency virus-1 (HIV-1) candidate applying a multiplex gRNA excision knockout gene edit using Cas9. EBT101 and is on track to advance into clinical trials in the fourth quarter of 2018 or first quarter of 2019.
“These newly discovered gene editors have the potential to offer flexibility and complementary gene editing approaches beyond the currently employed CRISPR/Cas9 for research and development of preventative and therapeutic strategies toward incurable diseases caused by pathogenic viruses in humans,” says Kamel Khalili Ph.D., Professor and Chair of Neuroscience, Lewis Katz School of Medicine at Temple University and founder and Principal Scientific Advisor to Excision BioTherapeutics.
“Advancements of this magnitude are exactly what makes ARTIS Ventures so proud to be backing exceptional companies in the biotech space such as Excision BioTherapeutics,” said Stuart Peterson, president of ARTIS Ventures. “We have the utmost confidence in what Thomas and his team are doing, having already made great progress on HIV with Cas9. These new editors add even greater potential and we look forward to seeing how they leverage them to improve lives.“
